Kyle Bruner

Patent Agent
Norton Rose Fulbright US LLP

United States
T:+1 512 536 3055
United States
T:+1 512 536 3055


Kyle Bruner is a patent agent with experience drafting and prosecuting patent applications in a diverse range of life science technologies. Kyle's recent work includes areas such as DNA sequencing, digital PCR, and molecular barcoding. His research background includes chemical synthesis, high throughput screening, proteomics, and cancer biology. Kyle's experience also includes patent strategy counseling and landscape analysis.

Professional experience

Expand all Collapse all

Ph.D, Cellular and Molecular Medicine, Johns Hopkins University School of Medicine, 2017
BS, summa cum laude, Biochemistry, University of Texas at Dallas, 2012

  • US Patent and Trademark Agent
  • Preparing office action responses, conducting examiner interviews, and other patent prosecution matters.
  • Formulating strategies for prosecution of foreign patent applications in various countries, including Europe, China, Australia, Japan, and India.
  • "Adaptation to tyrosine kinase inhibitor treatment reactivates ERK signaling in FLT3 and other receptor tyrosine kinase-driven leukemia,"Cancer Research, American Association for Cancer Research, October 2017
  • "Identification of novel small molecule modulators of K2P18.1 two-pore potassium channel," European Journal of Pharmacology, October 5, 2014
  • "Signaling adaptation to FLT3 inhibition in FLT3/ITD leukemia results in a reactivation of ERK signaling that can be abrogated with MEK inhibition," American Association for Cancer Research Annual Meeting, April 2016